Hormone therapy application rates were higher in the sBBC group than that in the mBBC group (82.1% vs. 61.9%, p = 0.045) despite no significant differences in ER and PR positivity of the invasive carcinomas between the first tumors of sBBC and mBBC in our study. Here, ESR1 is linked to invasive carcinoma.